BNP and NT-proBNP: Clinical Applications in (Suspicion of) Heart Failure
Joost H. RUTTEN*, Frans BOOMSMSA*, Anton H van den MEIRACKER*^,o
* Erasmus Medical Center, Department of Internal Medicine, Section of Vascular Pharmacology, Rotterdam, THE NETHERLANDS
 
^oCorresponding Author

Summary

The biologically active B-type natriuretic peptide (BNP) and the biologically inactive amino-terminal proBNP (NT-proBNP) are compounds produced by the heart that are released into the circulation and give information on the pump function of the heart. Reliable commercial assays are available for both peptides, some of which can be used for rapid point-of-care diagnosis. The accuracy of plasma BNP and NT-proBNP determinations in the diagnosis of heart failure is comparable. Introduction of rapid BNP determination in the Emergency Room for patients with acute dyspnea can lead to more efficient treatment. Sequential BNP or NT-proBNP measurements in patients with heart failure in the (outpatient) clinic can be helpful for optimizing treatment, leading to decreased heart failure-related morbidity and mortality. Measurement of BNP or NT-proBNP in the general population concentrafor early diagnosis of heart failure can not be recommended due to low specificity; plasma concentrations of BNP and NT-proBNP are also influenced by age, sex, body mass index, renal function and pulmonary pathology.